Last $8.11 USD
Change Today +0.14 / 1.76%
Volume 457.3K
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Snapshot

Open
$7.99
Previous Close
$7.97
Day High
$8.12
Day Low
$7.96
52 Week High
01/23/14 - $10.32
52 Week Low
04/15/14 - $6.36
Market Cap
533.1M
Average Volume 10 Days
960.4K
EPS TTM
$-1.12
Shares Outstanding
65.7M
EX-Date
12/18/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRUM PHARMACEUTICALS INC (SPPI)

spectrum pharmaceuticals inc (SPPI) Related Bloomberg News

View More Bloomberg News

spectrum pharmaceuticals inc (SPPI) Related Businessweek News

No Related Businessweek News Found

spectrum pharmaceuticals inc (SPPI) Details

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

226 Employees
Last Reported Date: 03/12/14
Founded in 1987

spectrum pharmaceuticals inc (SPPI) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.8M
President and Chief Operating Officer
Total Annual Compensation: $710.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $462.5K
Chief Medical Officer
Total Annual Compensation: $586.3K
Compensation as of Fiscal Year 2013.

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Spectrum Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $46,855,000 compared to $33,232,000 a year ago. Loss from operations was $1,396,000 compared to $12,529,000 a year ago. Loss before income taxes was $4,864,000 compared to $12,692,000 a year ago. Net loss was $3,563,000 or $0.06 basic and diluted per share compared to $9,721,000 or $0.16 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $46,855,000 compared to $33,232,000 a year ago. Non-GAAP income from operations was $8,106,000 compared to non-GAAP loss from operations of $5,159,000 a year ago. The company recorded non-GAAP net income of $6.828 million, or $0.09 per diluted share, compared to a non-GAAP net loss of $5.322 million, or $0.09 per basic and diluted share in the comparable period in 2013. For the six months period, the company reported total revenues of $86,979,000 compared to $71,899,000 a year ago. Loss from operations was $25,810,000 compared to $18,986,000 a year ago. Loss before income taxes was $32,427,000 compared to $20,467,000 a year ago. Net loss was $31,204,000 or $0.49 basic and diluted per share compared to $15,157,000 or $0.26 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $86,979,000 compared to $65,674,000 a year ago. Non-GAAP income from operations was $10,355,000 compared to non-GAAP loss from operations of $8,849,000 a year ago. The company recorded non-GAAP net income of $7.799 million, or $0.10 per diluted share, compared to a non-GAAP net loss of $10.330 million, or $0.18 per basic and diluted share in the comparable period in 2013.

Spectrum Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Spectrum Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Spectrum Pharmaceuticals, Inc. Receives FDA Approval for New Drug Application of Beleodaq

Spectrum Pharmaceuticals, Inc. received notification from the U.S. Food and Drug Administration of their early action granting accelerated approval of the company's New Drug Application for Beleodaq (belinostat) for Injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication was approved by FDA under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $8.11 USD +0.14

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.95 USD +0.08
CTI BioPharma Corp $2.56 USD +0.01
GlaxoSmithKline SAE £13.56 EGP +0.20
Pfizer Ltd/India 1,423 INR 0.00
Wyeth Ltd 985.00 INR 0.00
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit www.sppirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.